Brief: Tenax Therapeutics Announces Evaluation Of Strategic Alternatives

Tenax Therapeutics

15/09/2022 13:40

Sept 15 (Reuters) - Tenax Therapeutics Inc  TENX.O :
    * TENAX THERAPEUTICS ANNOUNCES THE EVALUATION OF STRATEGIC
ALTERNATIVES
    * TENAX THERAPEUTICS - ROTH CAPITAL PARTNERS WILL SUPPORT
TENAX
THERAPEUTICS AS FINANCIAL ADVISOR IN EVALUATING ALTERNATIVE
STRATEGIC PATHS
    * TENAX THERAPEUTICS - CO, BOARD BELIEVE CURRENT VALUATION
OF CO
DOES NOT ACCURATELY REFLECT POTENTIAL VALUE OF ITS
CLINICAL-STAGE PIPELINE
    * TENAX THERAPEUTICS - WILL EXPLORE DIVERSE RANGE OF
STRATEGIC
OPTIONS INCLUDING, AMONG OTHER THINGS, A SALE, MERGER, OR OTHER
STRATEGIC TRANSACTION
    * TENAX THERAPEUTICS - SHIFTING ANTICIPATED LAUNCH OF
IMATINIB
PHASE 3 TRIAL IN PAH, PREVIOUSLY ANTICIPATED TO BEGIN IN 2H
2022, INTO 2023

Source text for Eikon:  ID:nGNX6gPwyQ 
Further company coverage:  TENX.O 

 ((Reuters.Briefs@thomsonreuters.com;))